Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Assets (2016 - 2025)

AC Immune has reported Assets over the past 11 years, most recently at $193.0 million for Q4 2025.

  • Quarterly Assets fell 26.78% to $193.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $193.0 million through Dec 2025, down 26.78% year-over-year, with the annual reading at $193.0 million for FY2025, 26.78% down from the prior year.
  • Assets was $193.0 million for Q4 2025 at AC Immune, down from $214.5 million in the prior quarter.
  • Over five years, Assets peaked at $283.5 million in Q4 2021 and troughed at $221524.5 in Q3 2021.
  • The 5-year median for Assets is $209.5 million (2022), against an average of $188.3 million.
  • Year-over-year, Assets tumbled 99.92% in 2021 and then soared 101044.55% in 2022.
  • A 5-year view of Assets shows it stood at $283.5 million in 2021, then crashed by 31.93% to $193.0 million in 2022, then rose by 6.78% to $206.1 million in 2023, then increased by 27.9% to $263.6 million in 2024, then dropped by 26.78% to $193.0 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Assets are $193.0 million (Q4 2025), $214.5 million (Q3 2025), and $229.8 million (Q2 2025).